Diabetic eye diseaseis the most common microvascular complication in the diabetic
population and remains a leading cause of blindness among working-age adults
inthedevelopedworld. Therecentintroductionoftherapies targeting the vascular permeability
factor and angiogenic mediator vascular endothelial growth factor (VEGF) has had a
profound impact on the treatment of patients with diabetic eye disease. Clinical trials
assessing the efficacy of anti-VEGF therapies have demonstrated a response to treatment in …